Last 7 days
-1.9%
Last 30 days
-1.6%
Last 90 days
-26.3%
Trailing 12 Months
-49.2%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 119.1M | 121.1M | 119.5M | 0 |
2022 | 391.5M | 409.1M | 433.2M | 112.1M |
2021 | 85.7M | 93.4M | 38.4M | 383.0M |
2020 | 15.0M | 15.0M | 77.8M | 78.0M |
2019 | 8.9M | 9.4M | 6.8M | 15.0M |
2018 | 2.7M | 3.9M | 8.0M | 8.4M |
2017 | 0 | 0 | 0 | 1.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 01, 2023 | azoy alexander | sold | -4,215 | 14.95 | -282 | chief accounting officer |
Sep 22, 2023 | jarrett jennifer | sold | -427,166 | 19.99 | -21,369 | chief operating officer |
Sep 18, 2023 | nuyten dimitry sa | back to issuer | -75,643 | 20.4 | -3,708 | chief medical officer |
Sep 18, 2023 | jarrett jennifer | back to issuer | -255,122 | 20.4 | -12,506 | chief operating officer |
Jul 28, 2023 | jarrett jennifer | sold | -911,250 | 20.25 | -45,000 | chief operating officer |
Jul 03, 2023 | azoy alexander | sold | -20,777 | 20.41 | -1,018 | chief accounting officer |
Jun 28, 2023 | gilead sciences, inc. | bought | 19,452,600 | 19.26 | 1,010,000 | - |
Jun 22, 2023 | jarrett jennifer | sold | -237,795 | 19.12 | -12,437 | chief operating officer |
Jun 16, 2023 | tang carolyn c. | back to issuer | -55,960 | 19.35 | -2,892 | general counsel |
Jun 16, 2023 | jaen juan c. | back to issuer | -93,267 | 19.35 | -4,820 | president |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Dec 07, 2023 | Hudson Bay Capital Management LP | added | 39.13 | 536,350 | 2,872,000 | 0.01% |
Dec 06, 2023 | CITIGROUP INC | added | 20.79 | 165,515 | 2,615,840 | -% |
Dec 04, 2023 | TUCKER ASSET MANAGEMENT LLC | sold off | -100 | -1,016 | - | -% |
Nov 29, 2023 | Decheng Capital Management III (Cayman), LLC | unchanged | - | -2,052,700 | 15,612,700 | 4.99% |
Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 14.4 | 5,272 | 482,029 | -% |
Nov 22, 2023 | KBC Group NV | unchanged | - | - | 82,000 | -% |
Nov 22, 2023 | Public Sector Pension Investment Board | reduced | -29.04 | -707,463 | 1,190,120 | 0.01% |
Nov 21, 2023 | Walleye Trading LLC | reduced | -54.4 | -924,068 | 623,798 | -% |
Nov 21, 2023 | COMERICA BANK | added | 2,827 | 441,965 | 441,965 | -% |
Nov 21, 2023 | Walleye Capital LLC | added | 4.51 | -251,882 | 3,047,800 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jul 06, 2023 | gilead sciences, inc. | 35% | 25,586,953 | SC 13D/A | |
Feb 14, 2023 | biotechnology value fund l p | 1.7% | 1,236,002 | SC 13G/A | |
Feb 14, 2023 | pfm health sciences, lp | 3.7% | 6 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.04% | 4,373,177 | SC 13G | |
Jan 26, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
Oct 17, 2022 | pfm health sciences, lp | 5.5% | 6 | SC 13G | |
May 09, 2022 | blackrock inc. | 11.1% | 7,967,677 | SC 13G | |
Mar 14, 2022 | biotechnology value fund l p | 3.0% | 2,156,510 | SC 13G | |
Feb 14, 2022 | ecor1 capital, llc | 7.9% | 5,523,358 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Dec 05, 2023 | 4 | Insider Trading | |
Nov 07, 2023 | 8-K | Current Report | |
Nov 07, 2023 | 10-Q | Quarterly Report | |
Sep 26, 2023 | 4 | Insider Trading | |
Sep 22, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 20, 2023 | 4 | Insider Trading | |
Sep 20, 2023 | 4 | Insider Trading | |
Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 15, 2023 | 144 | Notice of Insider Sale Intent |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HILS | 31.5B | - | 6.13% | 411799.31% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 12.59% | -56.51% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 0.38% | -28.56% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 8.71% | -10.95% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 1.18% | -34.97% | 28.84 | 3.4 | 8.35% | -51.49% |
MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 33.62% | 24.68% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 10.65% | 240.88% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -9.53% | 43.40% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 14.00% | -9.85% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.63% | -24.14% | -12.52 | 10.67 | -1.03% | -16.59% |
SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 12.92% | -15.71% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -18.09% | -67.84% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.35% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 385.71% | 119.35% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 40.31% | 4064.72% | -0.5 | - | - | -13.74% |
Income Statement (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 10.3% | 32,000,000 | 29,000,000 | 25,000,000 | 33,537,000 | 33,581,000 | 27,000,000 | 18,000,000 | 354,617,000 | 9,461,000 | 9,461,000 | 9,461,000 | 9,970,000 | 64,530,000 | 1,750,000 | 1,750,000 | 9,750,000 | 1,750,000 | 1,750,000 | 1,750,000 | 1,562,000 | 4,291,000 |
Operating Expenses | 0% | 112,000,000 | 112,000,000 | 111,000,000 | 108,059,000 | 102,978,000 | 96,000,000 | 85,000,000 | 73,598,000 | 87,597,000 | 85,597,000 | 82,208,000 | 61,499,000 | 62,978,000 | 47,125,000 | 30,150,000 | 27,277,000 | 24,999,000 | 30,910,000 | 20,523,000 | 15,046,000 | 16,436,000 |
S&GA Expenses | 7.1% | 30,000,000 | 28,000,000 | 30,000,000 | 27,801,000 | 26,294,000 | 26,000,000 | 24,000,000 | 23,010,000 | 16,343,000 | 16,826,000 | 15,821,000 | 13,383,000 | 11,177,000 | 11,432,000 | 7,008,000 | 6,590,500 | 7,758,000 | 5,911,000 | 4,969,000 | 3,610,000 | 3,577,000 |
R&D Expenses | -2.4% | 82,000,000 | 84,000,000 | 81,000,000 | 80,258,000 | 76,684,000 | 70,000,000 | 61,000,000 | 50,588,000 | 71,254,000 | 68,771,000 | 66,387,000 | 48,364,000 | 51,801,000 | 35,693,000 | 23,142,000 | 20,686,500 | 17,241,000 | 24,999,000 | 15,554,000 | 11,436,000 | 12,859,000 |
EBITDA Margin | -3.0% | -2.36 | -2.29 | -2.27 | -2.32 | 0.21 | 0.18 | -0.72 | 0.15 | -7.76 | -3.16 | -1.41 | -1.54 | -1.05 | -5.43 | -5.43 | - | - | - | - | - | - |
Income Taxes | 100.0% | 2,000,000 | 1,000,000 | 2,000,000 | -2,000 | - | - | 1,000,000 | 2,000,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 6.8% | -69,000,000 | -74,000,000 | -78,000,000 | -67,270,500 | -64,919,000 | -67,000,000 | -67,000,000 | 281,538,000 | -77,975,000 | -75,970,000 | -72,593,000 | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -2.8% | -2.41 | -2.35 | -2.33 | -2.37 | 0.19 | 0.17 | -0.73 | 0.14 | -7.85 | -3.20 | -1.44 | -1.58 | -1.09 | -5.65 | -5.65 | - | - | - | - | - | - |
Net Income | 5.3% | -71,000,000 | -75,000,000 | -80,000,000 | -67,268,500 | -64,919,000 | -67,000,000 | -68,000,000 | 279,538,000 | -77,975,000 | -75,970,000 | -72,593,000 | -51,853,000 | 1,822,000 | -45,074,000 | -27,753,000 | -16,598,000 | -22,352,000 | -28,090,000 | -17,670,000 | -12,295,000 | -10,812,000 |
Net Income Margin | -3.5% | -2.45 | -2.37 | -2.34 | -2.38 | 0.18 | 0.16 | 0.15 | 0.14 | -7.35 | -2.14 | -1.97 | -1.58 | -1.13 | -7.45 | -6.32 | - | - | - | - | - | - |
Free Cashflow | -17.7% | -73,000,000 | -62,000,000 | -101,000,000 | -70,119,000 | -82,277,000 | -66,817,000 | 651,213,000 | -70,609,000 | -61,615,000 | -80,068,000 | -69,957,000 | -51,399,000 | 215,194,000 | -24,194,000 | -31,486,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -2.4% | 1,191 | 1,220 | 1,254 | 1,345 | 1,394 | 1,477 | 1,543 | 1,592 | 839 | 899 | 935 | 772 | 811 | 481 | 176 | 203 | 217 | 239 | 259 | 275 | 287 |
Current Assets | -10.5% | 882 | 986 | 1,015 | 1,067 | 1,101 | 1,227 | 1,264 | 1,262 | 545 | 746 | 842 | 736 | 797 | 472 | 166 | 193 | 200 | 228 | 245 | 259 | 265 |
Cash Equivalents | -20.0% | 184 | 230 | 238 | 206 | 218 | 273 | 549 | 148 | 179 | 320 | 390 | 173 | 222 | 285 | 67.00 | 58.00 | 79.00 | 76.00 | 68.00 | 71.00 | 75.00 |
Net PPE | 11.1% | 50.00 | 45.00 | 37.00 | 35.00 | 34.00 | 33.00 | 33.00 | 32.00 | 29.00 | 24.00 | 15.00 | 11.00 | 9.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 12.00 |
Liabilities | - | - | - | - | - | 695 | 729 | 747 | 750 | 297 | 294 | 270 | 270 | 267 | 53.00 | 36.00 | 39.00 | 40.00 | 42.00 | 37.00 | 40.00 | 42.00 |
Current Liabilities | 11.1% | 200 | 180 | 179 | 193 | 177 | 164 | 161 | 166 | 143 | 130 | 132 | 122 | 163 | 40.00 | 21.00 | 23.00 | 21.00 | 27.00 | 19.00 | 17.00 | 17.00 |
Shareholder's Equity | -8.1% | 520 | 566 | 600 | 657 | 699 | 747 | 797 | 842 | 543 | 605 | 665 | 502 | 544 | 429 | 141 | 164 | 177 | 197 | 222 | 235 | 245 |
Retained Earnings | -10.2% | -768 | -697 | -622 | -542 | -474 | -409 | -343 | -275 | -554 | -476 | -400 | -328 | -276 | -278 | -233 | -205 | -188 | -166 | -138 | -122 | -110 |
Additional Paid-In Capital | - | - | - | - | - | 1,183 | 1,165 | 1,145 | 1,118 | 1,097 | 1,081 | 1,066 | 830 | 821 | 707 | 373 | 369 | 366 | 363 | 360 | 358 | 356 |
Shares Outstanding | 0.4% | 75.00 | 75.00 | 73.00 | 73.00 | 72.00 | 72.00 | 71.00 | 71.00 | 70.00 | 70.00 | 67.00 | 65.00 | 63.00 | 49.00 | 44.00 | 46.00 | 44.00 | 44.00 | 44.00 | 35.00 | 43.00 |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -10.5% | -63,000 | -57,000 | -98,000 | -69,739 | -81,261 | -65,000 | 654,000 | -61,932 | -53,757 | -73,995 | -66,316 | -50,050 | 216,265 | -23,938 | -31,277 | -9,471 | -27,399 | -19,753 | -16,839 | -7,107 | -11,765 |
Share Based Compensation | 0% | 18,000 | 18,000 | 19,000 | 16,522 | 16,478 | 15,000 | 17,000 | 14,287 | 14,585 | 13,367 | 12,761 | 8,066 | 6,002 | 4,470 | 3,462 | 2,437 | 2,740 | 2,130 | 1,674 | 1,054 | 1,048 |
Cashflow From Investing | -57.7% | 11,000 | 26,000 | 129,000 | 46,811 | 23,189 | -215,000 | -268,000 | 18,782 | -88,611 | 3,003 | 62,826 | 136 | -387,119 | -87,073 | 40,056 | -12,104 | 30,364 | 26,673 | 14,279 | 2,511 | -83,337 |
Cashflow From Financing | -73.9% | 6,000 | 23,000 | 1,000 | 11,195 | 2,805 | 4,000 | 15,000 | 11,331 | 1,318 | 2,231 | 222,120 | 2,002 | 107,518 | 328,870 | 610 | 520 | -41.00 | 649 | -5.00 | 771 | -7.00 |
Condensed Consolidated Statements of Operations - USD ($) shares in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenues: | ||||
Total revenues | $ 32,000,000 | $ 33,000,000 | $ 86,000,000 | $ 78,000,000 |
Operating expenses: | ||||
Research and development (Net of recoveries of $22, $27, $89 and $93 from a related party) | 82,000,000 | 77,000,000 | 247,000,000 | 208,000,000 |
General and administrative | 30,000,000 | 26,000,000 | 88,000,000 | 76,000,000 |
Total operating expenses | 112,000,000 | 103,000,000 | 335,000,000 | 284,000,000 |
Loss from operations | (80,000,000) | (70,000,000) | (249,000,000) | (206,000,000) |
Non-operating income (expense): | ||||
Interest and other income, net | 12,000,000 | 5,000,000 | 30,000,000 | 8,000,000 |
Effective interest on liability for sale of future royalties | (1,000,000) | 0 | (2,000,000) | (1,000,000) |
Total non-operating income, net | 11,000,000 | 5,000,000 | 28,000,000 | 7,000,000 |
Loss before income taxes | (69,000,000) | (65,000,000) | (221,000,000) | (199,000,000) |
Income tax expense | (2,000,000) | 0 | (5,000,000) | (1,000,000) |
Net loss | $ (71,000,000) | $ (65,000,000) | $ (226,000,000) | $ (200,000,000) |
Net loss per share, basic (in dollars per share) | $ (0.94) | $ (0.90) | $ (3.07) | $ (2.78) |
Net loss per share, diluted (in dollars per share) | $ (0.94) | $ (0.90) | $ (3.07) | $ (2.78) |
Shares used to compute net loss per share, basic (in shares) | 74.6 | 72.2 | 73.6 | 71.8 |
Shares used to compute net loss per share, diluted (in shares) | 74.6 | 72.2 | 73.6 | 71.8 |
License and Development Services Revenue | ||||
Revenues: | ||||
Total revenues | $ 22,000,000 | $ 23,000,000 | $ 58,000,000 | $ 48,000,000 |
Other Collaboration Revenue | ||||
Revenues: | ||||
Total revenues | $ 10,000,000 | $ 10,000,000 | $ 28,000,000 | $ 30,000,000 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 184 | $ 206 |
Marketable securities | 615 | 803 |
Receivable from collaboration partners ($22 and $39 from a related party) | 52 | 39 |
Prepaid expenses and other current assets | 31 | 19 |
Total current assets | 882 | 1,067 |
Long-term marketable securities | 151 | 129 |
Property and equipment, net | 50 | 35 |
Other noncurrent assets ($6 and $2 from a related party) | 108 | 114 |
Total assets | 1,191 | 1,345 |
Current liabilities: | ||
Accounts payable | 17 | 20 |
Deferred revenue ($96 and $97 to a related party) | 103 | 97 |
Other current liabilities | 80 | 76 |
Total current liabilities | 200 | 193 |
Deferred revenue, noncurrent ($309 and $355 to a related party) | 326 | 355 |
Other noncurrent liabilities | 145 | 140 |
Commitments | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding. | 0 | 0 |
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,291 | 1,206 |
Accumulated deficit | (768) | (542) |
Accumulated other comprehensive loss | (3) | (7) |
Total stockholders’ equity | 520 | 657 |
Total liabilities and stockholders’ equity | $ 1,191 | $ 1,345 |
 CEO | Dr. Terry J. Rosen Ph.D. |
---|---|
 WEBSITE | www.arcusbio.com |
 EMPLOYEES | 500 |